TY - JOUR
T1 - Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease
AU - Nowak, Kristen L.
AU - You, Zhiying
AU - Gitomer, Berenice
AU - Brosnahan, Godela
AU - Torres, Vicente E.
AU - Chapman, Arlene B.
AU - Perrone, Ronald D.
AU - Steinman, Theodore I.
AU - Abebe, Kaleab Z.
AU - Rahbari-Oskoui, Frederic F.
AU - Yu, Alan S.L.
AU - Harris, Peter C.
AU - Bae, Kyongtae T.
AU - Hogan, Marie
AU - Miskulin, Dana
AU - Chonchol, Michel
N1 - Funding Information:
K.L.N. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), K01 DK103678. The Halt Progression of Polycystic Kidney Disease studies were supported by the NIDDK grants U01 DK062402, U01 DK062410, U01 CK082230, U01 DK062408, and U01 DK062401; the National Center for Research Resources General Clinical Research Centers (RR000039 to Emory University, RR000585 to the Mayo Clinic, RR000054 to Tufts Medical Center, RR000051 to the University of Colorado, RR023940 to the University of Kansas Medical Center, and RR001032 to Beth Israel Deaconess Medical Center); the National Center for Advancing Translational Sciences Clinical and Translational Science Awards (RR025008 and TR000454 to Emory University, RR024150 and TR00135 to the Mayo Clinic, RR025752 and TR001064 to Tufts University, RR025780 and TR001082 to the University of Colorado, RR025758 and TR001102 to Beth Israel Deaconess Medical Center, RR033179 and TR000001 to the University of Kansas Medical Center, and RR024989 and TR000439 to Cleveland Clinic); by funding from the Zell Family Foundation (to the University of Colorado); and by a grant from the Polycystic Kidney Disease Foundation.
Funding Information:
K.L.N. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), K01 DK103678. The Halt Progression of Polycystic Kidney Disease studies were supported by the NIDDK grants U01 DK062402, U01 DK062410, U01 CK082230, U01 DK062408, and U01 DK062401; the National Center for Research Resources General Clinical Research Centers (RR000039 to Emory University, RR000585 to the Mayo Clinic, RR000054 to Tufts Medical Center, RR000051 to the University of Colorado, RR023940 to the University of Kansas Medical Center, and RR001032 to Beth Israel Deaconess Medical Center); the National Center for Advancing Translational Sciences Clinical and Translational Science Awards (RR025008 and TR000454 to Emory University, RR024150 and TR00135 to the Mayo Clinic, RR025752 and TR001064 to Tufts University, RR025780 and TR001082 to the University of Colorado, RR025758 and TR001102 to Beth Israel Deaconess Medical Center, RR033179 and TR000001 to the University of Kansas Medical Center, and RR024989 and TR000439 to Cleveland Clinic); by funding from the Zell Family Foundation (to the University of Colorado); and by a grant from the Polycystic Kidney Disease Foundation. The funding agencies had no direct role in the conduct of the study; the collection, management, analyses, and interpretation of the data; or preparation or approval of the manuscript.
Publisher Copyright:
Copyright © 2018 by the American Society of Nephrology
PY - 2018/2
Y1 - 2018/2
N2 - The association of overweight/obesity with disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) remains untested. We hypothesized that overweight/obesity associates with faster progression in early-stage ADPKD. Overall, 441 nondiabetic participants with ADPKD and an eGFR.60 ml/min per 1.73 m2 who participated in the Halt Progression of Polycystic Kidney Disease Study A were categorized on the basis of body mass index (BMI; calculated using nonkidney and nonliver weight) as normal weight (18.5-24.9 kg/m2; reference; n=192), overweight (25.0-29.9 kg/m2; n=168), or obese ($30 kg/m2; n=81). We evaluated the longitudinal (5-year) association of overweight/obesity with change in total kidney volume (TKV) by magnetic resonance imaging using linear regression and multinomial logistic regression models. Among participants, mean6SD age was 3768 years, annual percent change in TKV was 7.4%65.1%, and BMI was 26.364.9 kg/m2. The annual percent change in TKV increased with increasing BMI category (normal weight: 6.1%64.7%, overweight: 7.9%64.8%, obese: 9.4%66.2%; P,0.001). In the fully adjusted model, higher BMI associated with greater annual percent change in TKV (b=0.79; 95% confidence interval [95% CI], 0.18 to 1.39, per 5-unit increase in BMI). Overweight and obesity associated with increased odds of annual percent change in TKV $7% compared with,5% (overweight: odds ratio, 2.02; 95% CI, 1.15 to 3.56; obese: odds ratio, 3.76; 95% CI, 1.81 to 7.80). Obesity also independently associated with greater eGFR decline (slope) versus normal weight (fully adjusted b =20.08; 95% CI, 20.15 to 20.02). In conclusion, overweight and, particularly, obesity are strongly and independently associated with rate of progression in early-stage ADPKD.
AB - The association of overweight/obesity with disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) remains untested. We hypothesized that overweight/obesity associates with faster progression in early-stage ADPKD. Overall, 441 nondiabetic participants with ADPKD and an eGFR.60 ml/min per 1.73 m2 who participated in the Halt Progression of Polycystic Kidney Disease Study A were categorized on the basis of body mass index (BMI; calculated using nonkidney and nonliver weight) as normal weight (18.5-24.9 kg/m2; reference; n=192), overweight (25.0-29.9 kg/m2; n=168), or obese ($30 kg/m2; n=81). We evaluated the longitudinal (5-year) association of overweight/obesity with change in total kidney volume (TKV) by magnetic resonance imaging using linear regression and multinomial logistic regression models. Among participants, mean6SD age was 3768 years, annual percent change in TKV was 7.4%65.1%, and BMI was 26.364.9 kg/m2. The annual percent change in TKV increased with increasing BMI category (normal weight: 6.1%64.7%, overweight: 7.9%64.8%, obese: 9.4%66.2%; P,0.001). In the fully adjusted model, higher BMI associated with greater annual percent change in TKV (b=0.79; 95% confidence interval [95% CI], 0.18 to 1.39, per 5-unit increase in BMI). Overweight and obesity associated with increased odds of annual percent change in TKV $7% compared with,5% (overweight: odds ratio, 2.02; 95% CI, 1.15 to 3.56; obese: odds ratio, 3.76; 95% CI, 1.81 to 7.80). Obesity also independently associated with greater eGFR decline (slope) versus normal weight (fully adjusted b =20.08; 95% CI, 20.15 to 20.02). In conclusion, overweight and, particularly, obesity are strongly and independently associated with rate of progression in early-stage ADPKD.
UR - http://www.scopus.com/inward/record.url?scp=85041477827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041477827&partnerID=8YFLogxK
U2 - 10.1681/ASN.2017070819
DO - 10.1681/ASN.2017070819
M3 - Article
C2 - 29118087
AN - SCOPUS:85041477827
SN - 1046-6673
VL - 29
SP - 571
EP - 578
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 2
ER -